The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vanasek, T. L.
Right arrow Articles by Mueller, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vanasek, T. L.
Right arrow Articles by Mueller, D. L.
The Journal of Immunology, 2001, 167: 5636-5644.
Copyright © 2001 by The American Association of Immunologists

Antagonistic Roles for CTLA-4 and the Mammalian Target of Rapamycin in the Regulation of Clonal Anergy: Enhanced Cell Cycle Progression Promotes Recall Antigen Responsiveness1

Tracy L. Vanasek*, Alexander Khoruts*, Traci Zell{dagger} and Daniel L. Mueller2,*

Departments of * Medicine and {dagger} Microbiology and Center for Immunology, University of Minnesota Medical School, Minneapolis, MN 55455

CD4+ T cells that undergo multiple rounds of cell division during primary Ag challenge in vivo produce IL-2 on secondary Ag rechallenge, whereas cells that fail to progress through the cell cycle are anergic to restimulation. Anti-CTLA-4 mAb treatment during primary Ag exposure increases cell cycle progression and enhances recall Ag responsiveness; however, simultaneous treatment with rapamycin, an inhibitor of the mammalian target of rapamycin and potent antiproliferative agent, prevents both effects. The data suggest that cell cycle progression plays a primary role in the regulation of recall Ag responsiveness in CD4+ T cells in vivo. CTLA-4 molecules promote clonal anergy development only indirectly by limiting cell cycle progression during the primary response.




This article has been cited by other articles:


Home page
J. Immunol.Home page
Y. Zheng, G. M. Delgoffe, C. F. Meyer, W. Chan, and J. D. Powell
Anergic T Cells Are Metabolically Anergic
J. Immunol., November 15, 2009; 183(10): 6095 - 6101.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. Kurtz, F. Raval, C. Vallot, J. Der, and M. Sykes
CTLA-4 on alloreactive CD4 T cells interacts with recipient CD80/86 to promote tolerance
Blood, April 9, 2009; 113(15): 3475 - 3484.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
R. Zhang, N. Zhang, and D. L. Mueller
Casitas B-Lineage Lymphoma b Inhibits Antigen Recognition and Slows Cell Cycle Progression at Late Times during CD4+ T Cell Clonal Expansion
J. Immunol., October 15, 2008; 181(8): 5331 - 5339.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
C. Lagaraine, R. Lemoine, C. Baron, H. Nivet, F. Velge-Roussel, and Y. Lebranchu
Induction of human CD4+ regulatory T cells by mycophenolic acid-treated dendritic cells
J. Leukoc. Biol., October 1, 2008; 84(4): 1057 - 1064.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
J. Kang, S. J. Huddleston, J. M. Fraser, and A. Khoruts
De novo induction of antigen-specific CD4+CD25+Foxp3+ regulatory T cells in vivo following systemic antigen administration accompanied by blockade of mTOR
J. Leukoc. Biol., May 1, 2008; 83(5): 1230 - 1239.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
Y. Zheng, S. L. Collins, M. A. Lutz, A. N. Allen, T. P. Kole, P. E. Zarek, and J. D. Powell
A Role for Mammalian Target of Rapamycin in Regulating T Cell Activation versus Anergy
J. Immunol., February 15, 2007; 178(4): 2163 - 2170.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
T. L. Vanasek, S. L. Nandiwada, M. K. Jenkins, and D. L. Mueller
CD25+Foxp3+ Regulatory T Cells Facilitate CD4+ T Cell Clonal Anergy Induction during the Recovery from Lymphopenia
J. Immunol., May 15, 2006; 176(10): 5880 - 5889.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Allen, Y. Zheng, L. Gardner, M. Safford, M. R. Horton, and J. D. Powell
The Novel Cyclophilin Binding Compound, Sanglifehrin A, Disassociates G1 Cell Cycle Arrest from Tolerance Induction
J. Immunol., April 15, 2004; 172(8): 4797 - 4803.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. L. Bonnevier and D. L. Mueller
Cutting Edge: B7/CD28 Interactions Regulate Cell Cycle Progression Independent of the Strength of TCR Signaling
J. Immunol., December 15, 2002; 169(12): 6659 - 6663.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. Colombetti, F. Benigni, V. Basso, and A. Mondino
Clonal Anergy Is Maintained Independently of T Cell Proliferation
J. Immunol., December 1, 2002; 169(11): 6178 - 6186.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
L. S. K. Walker, L. J. Ausubel, A. Chodos, N. Bekarian, and A. K. Abbas
CTLA-4 Differentially Regulates T Cell Responses to Endogenous Tissue Protein Versus Exogenous Immunogen
J. Immunol., December 1, 2002; 169(11): 6202 - 6209.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
H. Matsue, C. Yang, K. Matsue, D. Edelbaum, M. Mummert, and A. Takashima
Contrasting Impacts of Immunosuppressive Agents (Rapamycin, FK506, Cyclosporin A, and Dexamethasone) on Bidirectional Dendritic Cell-T Cell Interaction During Antigen Presentation
J. Immunol., October 1, 2002; 169(7): 3555 - 3564.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. D. Higgins, M. A. Mihalyo, P. W. McGary, and A. J. Adler
CD4 Cell Priming and Tolerization Are Differentially Programmed by APCs upon Initial Engagement
J. Immunol., June 1, 2002; 168(11): 5573 - 5581.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2001 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2001 by The American Association of Immunologists, Inc. All rights reserved.